A Multivalent Peptide Vaccine Against Malaria, Targeting Plasmodium Circumsporozoite Protein and Mosquito AgTRIO.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40804022.
- Also identified by DOI 10.1093/infdis/jiaf432 and PMC identifier 12965381.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Malaria begins when an infected mosquito injects saliva containing Plasmodium sporozoites into the host skin. The immune response against a mosquito saliva protein, AgTRIO, reduces Plasmodium infection and can work in combination with antibody against the Plasmodium circumsporozoite protein (CSP). We have now developed a chimeric peptide, PfAg, containing regions from Plasmodium falciparum CSP (PfCSP) and AgTRIO. Mice administered PfAg generated robust humoral responses against both PfCSP and AgTRIO. After exposure to PfCSP-expressing Plasmodium berghei-infected mosquitoes, PfAg-immunized inbred C57BL/6 and outbred CD-1 mice had significantly improved survival compared with control animals. These data will aid in the development of a new malaria vaccine.
Medical subject headings
- Protozoan Proteins
- Malaria Vaccines
- Plasmodium falciparum
- Salivary Proteins and Peptides
- Malaria
- Insect Proteins